The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Open accessAbstract
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH.Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6.Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group).Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes.Funding Intercept Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More recently, the interim analysis at month 18 of the phase 3 trial REGENERATE showed that 23% and 18% of the subjects in the 25 mg and 10 mg group respectively vs 12% in the placebo group met the primary endpoint, i.e., fibrosis improvement by at least one stage with no worsening of NASH with a similar adverse event and safety profile compared to the phase 2 trial [81].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, OCA led to a small but significant reduction in fibrosis in NAFLD patients.[71]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“REGENERATE (phase 3)78: 18-month interim analysis in patients with non-cirrhotic NASH (F2 or F3) showed that 25 mg OCA significantly improved fibrosis by >1 stage (23% vs 12% under placebo) but not NASH (12% vs 8%, n.s.).”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the response rate of OCA treatment to NASH-induced liver fibrosis is only 23%.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Improvement in fibrosis was seen in 12% of the placebo group, 18% with obeticholic acid 10 mg (p = 0.045) and 23% in the obeticholic acid 25 mg (p = 0.0002) group.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [47]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Self-citationMarcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Cited by
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Self-citation
Metadata
- Authors
- Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L. L., Dufour, J.-F., Shapiro, D., Campagna, J., Zaru, L., MacConell, L., Shringarpure, R., Harrison, S., Sanyal, A. J., Abdelmalek, M., Abrams, G., Aguilar, H., Ahmed, A., Aigner, E., Aithal, G., Ala, A., Alazawi, W., Albillos, A., Allison, M., Al-Shamma, S., Andrade, R., Andreone, P., Angelico, M., Ankoma-Sey, V., Anstee, Q., Anty, R., Araya, V., Arenas Ruiz, J. I., Arkkila, P., Arora, M., Asselah, T., Au, J., Ayonrinde, O., Bailey, R. J., Balakrishnan, M., Bambha, K., Bansal, M., Barritt, S., Bate, J., Beato, J., Beckebaum, S., Behari, J., Bellot, P., Ben Ari, Z., Bennett, M., Berenguer, M., Beretta-Piccoli, B. T., Berg, T., Bonacini, M., Bonet, L., Borg, B., Bourliere, M., Boursier, J., Bowman, W., Bradley, D., Brankovic, M., Braun, M., Bronowicki, J.-P., Bruno, S., Bugianesi, E., Cai, C., Calderon, A., Calleja Panero, J. L., Carey, E., Carmiel, M., Carrión, J. A., Cave, M., Chagas, C., Chami, T., Chang, A., Coates, A., Cobbold, J., Costentin, C., Corey, K., Corless, L., Cortez-Pinto, H., Crespo, J., Cruz Pereira, O., de Ledinghen, V., deLemos, A., Diago, M., Dong, M., Dufour, J.-F., Dugalic, P., Dunn, W., Elkhashab, M., Epstein, M., Escudero-Garcia, M. D., Etzion, O., Evans, L., Falcone, R., Fernandez, C., Ferreira, J., Fink, S., Finnegan, K., Firpi-Morell, R., Floreani, A., Fontanges, T., Ford, R., Forrest, E., Fowell, A., Fracanzani, A. L., Francque, S., Freilich, B., Frias, J., Fuchs, M., Fuentes, J., Galambos, M., Gallegos, J., Geerts, A., Geier, A., George, J., Ghali, M., Ghalib, R., Gholam, P., Gines, P., Gitlin, N., Gluud, L. L., Goeser, T., Goff, J., Gordon, S., Gordon, F., Goria, O., Greer, S., Grigorian, A., Gronbaek, H., Guillaume, M., Gunaratnam, N., Halegoua-De Marzio, D., Hameed, B., Hametner, S., Hamilton, J., Harrison, S., Hartleb, M., Hassanein, T., Häussinger, D., Hellstern, P., Herring, R., Heurich, E., Hezode, C., Hinrichsen, H., Holland Fischer, P., Horsmans, Y., Huang, J., Hussaini, H., Jakiche, A., Jeffers, L., Jones, B., Jorge, R., Jorquera, F., Joshi, S., Kahraman, A., Kaita, K., Karyotakis, N., Kayali, Z., Kechagias, S., Kepczyk, T., Khalili, M., Khallafi, H., Kluwe, J., Knapple, W., Kohli, A., Korenblat, K., Kowdley, K., Krag, A., Krause, R., Kremer, A., Krok, K., Krstic, M., Kugelmas, M., Kumar, S., Kuwada, S., Labarriere, D., Lai, M., Laleman, W., Lampertico, P., Lawitz, E., Lee, A., Leroy, V., Lidofsky, S., Lim, T. H., Lim, J., Lipkis, D., Little, E., Lonardo, A., Long, M., Loomba, R., Luketic, V. A. C., Lurie, Y., Macedo, G., Magalhaes, J., Makara, M., Maliakkal, B., Manns, M., Manousou, P., Mantry, P., Marchesini, G., Marinho, C., Marotta, P., Marschall, H.-U., Martinez, L., Mathurin, P., Mayo, M., Mazzella, G., McCullen, M., McLaughlin, W., Merle, U., Merriman, R., Modi, A., Molina, E., Montano-Loza, A., Monteverde, C., Morales Cardona, A., Moreea, S., Moreno, C., Morisco, F., Mubarak, A., Muellhaupt, B., Mukherjee, S., Müller, T., Nagorni, A., Naik, J., Neff, G., Nevah, M., Newsome, P., Nguyen-Khac, E., Noureddin, M., Oben, J., Olveira, A., Orlent, H., Orr, D., Orr, J., Ortiz-Lasanta, G., Ozenne, V., Pandya, P., Paredes, A., Park, J., Patel, J., Patel, K., Paul, S., Patton, H., Peck-Radosavljevic, M., Petta, S., Pianko, S., Piekarska, A., Pimstone, N., Pisegna, J., Pockros, P., Pol, S., Porayko, M., Poulos, J., Pound, D., Pouzar, J., Presa Ramos, J., Pyrsopoulos, N., Rafiq, N., Muller, K., Ramji, A., Ratziu, V., Ravinuthala, R., Reddy, C., Reddy K G, G., Reddy K R, K. R., Regenstein, F., Reindollar, R., Reynolds, J., Riera, A., Rinella, M., Rivera Acosta, J., Robaeys, G., Roberts, S., Rodriguez-Perez, F., Romero, S., Romero-Gomez, M., Rubin, R., Rumi, M., Rushbrook, S., Rust, C., Ryan, M., Safadi, R., Said, A., Salminen, K., Samuel, D., Santoro, J., Sanyal, A., Sarkar, S., Schaeffer, C., Schattenberg, J., Schiefke, I., Schiff, E., Schmidt, W., Schneider, J., Schouten, J., Schultz, M., Sebastiani, G., Semela, D., Sepe, T., Sheikh, A., Sheikh, M., Sheridan, D., Sherman, K., Shibolet, O., Shiffman, M., Siddique, A., Sieberhagen, C., Sigal, S., Sikorska, K., Simon, K., Sinclair, M., Skoien, R., Solis, J., Sood, S., Souder, B., Spivey, J., Stal, P., Stinton, L., Strasser, S., Svorcan, P., Szabo, G., Talal, A., Tam, E., Tetri, B., Thuluvath, P., Tobias, H., Tomasiewicz, K., Torres, D., Tran, A., Trauner, M., Trautwein, C., Trotter, J., Tsochatzis, E., Unitt, E., Vargas, V., Varkonyi, I., Veitsman, E., Vespasiani Gentilucci, U., Victor, D., Vierling, J., Vincent, C., Vincze, A., von der Ohe, M., Von Roenn, N., Vuppalanchi, R., Waters, M., Watt, K., Wattacheril, J., Weltman, M., Wieland, A., Wiener, G., Williams A, A., Williams J, J., Wilson, J., Yataco, M., Yoshida, E., Younes, Z., Yuan, L., Zivony, A., Zogg, D., Zoller, H., Zoulim, F., Zuckerman, E., & Zuin, M.
- Affiliations
- Inova Health System (US)
- Hospital Clínic de Barcelona (ES)
- Intercept Pharmaceuticals (United States) (US)
- Hôpital Beaujon (FR)
- University of Würzburg (DE)
- Auckland City Hospital (NZ)
- Pinnacle Clinical Research (US)
- University of Bologna (IT)
- The University of Texas at San Antonio Health Science Center (US)
- University of Turin (IT)
- ORCID
- Younossi, Zobair M
- Goodman, Zachary
- Graupera, Isabel
- Shringarpure, Reshma
- Abrams, Gary
- Aguilar, Humberto
- Ahmed, Aijaz
- Aigner, Elmar
- Aithal, Guruprasad
- Ala, Aftab
- Alazawi, William
- Allison, Michael
- Angelico, Mario
- Anty, Rodolphe
- Arkkila, Perttu
- Asselah, Tarik
- Au, Jennifer
- Ayonrinde, Oyekoya
- Balakrishnan, Maya
- Bambha, Kiran
- Bansal, Meena
- Behari, Jaideep
- Bellot, Pablo
- Berenguer, Marina
- Berg, Thomas
- Bonacini, Maurizio
- Borg, Brian
- Bradley, David
- Braun, Marius
- Bronowicki, Jean-Pierre
- Bruno, Savino
- Cai, Cindy
- Carey, Elizabeth
- Cave, Matthew
- Cobbold, Jeremy
- Corey, Kathleen
- Corless, Lynsey
- Crespo, Javier
- deLemos, Andrew
- Etzion, Ohad
- Firpi-Morell, Roberto
- Floreani, Annarosa
- Fowell, Andrew
- Fracanzani, Anna Ludovica
- Francque, Sven
- Fuchs, Michael
- Fuentes, Javier
- Geerts, Anja
- Ghali, Maged
- Goeser, Tobias
- Gordon, Stuart
- Goria, Odile
- Greer, Shaun
- Hameed, Bilal
- Hartleb, Marek
- Hassanein, Tarek
- Huang, Jonathan
- Jorquera, Francisco
- Kayali, Zeid
- Kechagias, Stergios
- Khalili, Mandana
- Khallafi, Hicham
- Kluwe, Johannes
- Kohli, Anita
- Korenblat, Kevin
- Krag, Aleksander
- Kremer, Andreas
- Krok, Karen
- Krstic, Miodrag
- Kugelmas, Marcelo
- Kumar, Sonal
- Lai, Michelle
- Laleman, Wim
- Lee, Alice
- Leroy, Vincent
- Lidofsky, Steven
- Lim, Joseph
- Little, Ester
- Lonardo, Amadeo
- Long, Michelle
- Luketic, Velimir Anthony Christopher
- Lurie, Yoav
- Macedo, Guilherme
- Makara, Mihály
- Manns, Michael
- Manousou, Pinelopi
- Mantry, Parvez
- Marchesini, Giulio
- Marinho, Carla
- Marschall, Hanns-Ulrich
- Mayo, Marlyn
- Merle, Uta
- Modi, Apurva
- Molina, Esther
- Monteverde, Carlos
- Moreea, Sulleman
- Moreno, Christophe
- Morisco, Filomena
- Mubarak, Abdullah
- Mukherjee, Sandeep
- Müller, Tobias
- Neff, Guy
- Noureddin, Mazen
- Oben, Jude
- Orlent, Hans
- Ozenne, Violaine
- Paredes, Angelo
- Park, James
- Patel, Keyur
- Paul, Sonali
- Patton, Heather
- Petta, Salvatore
- Pianko, Stephen
- Piekarska, Anna
- Pisegna, Joseph
- Pockros, Paul
- Pol, Stanislas
- Porayko, Michael
- Pyrsopoulos, Nikolaos
- Muller, Kate
- Ramji, Alnoor
- Ravinuthala, Ravi
- Robaeys, Geert
- Roberts, Stuart
- Rubin, Raymond
- Rushbrook, Simon
- Ryan, Michael
- Safadi, Rifaat
- Said, Adnan
- Salminen, Kimmo
- Samuel, Didier
- Sarkar, Souvik
- Schattenberg, Jörn
- Schiff, Eugene
- Schultz, Michael
- Sebastiani, Giada
- Semela, David
- Sheikh, Aasim
- Sheikh, Muhammad
- Sherman, Kenneth
- Shibolet, Oren
- Shiffman, Mitchell
- Siddique, Asma
- Sieberhagen, Cyril
- Sigal, Samuel
- Sikorska, Katarzyna
- Simon, Krzysztof
- Sinclair, Marie
- Skoien, Richard
- Solis, Joel
- Sood, Siddharth
- Stal, Per
- Stinton, Laura
- Strasser, Simone
- Svorcan, Petar
- Talal, Andrew
- Tam, Edward
- Thuluvath, Paul
- Tomasiewicz, Krzysztof
- Torres, Dawn
- Tran, Albert
- Trauner, Michael
- Trautwein, Christian
- Veitsman, Ella
- Vierling, John
- Vincent, Catherine
- Vuppalanchi, Raj
- Watt, Kymberly
- Wattacheril, Julia
- Weltman, Martin
- Yoshida, Eric
- Younes, Ziad
- Yuan, Liyun
- Zoller, Heinz
- Zoulim, Fabien
- Zuin, Massimo
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 394
- Issue
- 10215
- Pages
- 2184-2196
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2993083975
- Cited by
- 1,277
- References
- 26
- Citations by year
- 2026: 132 · 2025: 144 · 2024: 167 · 2023: 213 · 2022: 210 · 2021: 229 · 2020: 176 · 2019: 3
- FWCI
- 118.18
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- PEARL (University of Plymouth) (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- PEARL (University of Plymouth) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- Medpace
- Arrowhead Pharmaceuticals
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research
- Children's Liver Disease Foundation
- Newcastle University
- Novo Nordisk
- Servier
- Genentech
- Allergan
- Novartis Pharma
- Birmingham Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- obeticholic acid, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, farnesoid X receptor agonist, liver fibrosis, NASH resolution, fibrosis regression, histological improvement, non-invasive fibrosis markers, liver enzymes, drug safety, cirrhosis prevention, dose comparison, comorbidities
- MeSH terms
- Administration, Oral, Biopsy, Chenodeoxycholic Acid, Double-Blind Method, Female, Humans, Liver Function Tests, Male, Middle Aged, Biomarkers, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)33041-7
- The paper
- Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., . . . Zuin, M. (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)33041-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.